Evidence map›Paper›PMID 30168618›Full record

ArticleLasers in surgery and medicine2019

Development and evaluation of a low-cost, portable, LED-based device for PDT treatment of early-stage oral cancer in resource-limited settings.

Hui Liu, Liam Daly, Grant Rudd, Amjad P Khan, Srivalleesha Mallidi, Yiran Liu, Filip Cuckov, Tayyaba Hasan, Jonathan P Celli

Abstract readEvaluation Study
In one paragraph

Article in Lasers in surgery and medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Engineered MoSNanomaterials (Basel, Switzerland) · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hui LiuDepartment of Physics, University of Massachusetts, Boston, Massachusetts, 02125.
Liam DalyDepartment of Engineering, University of Massachusetts, Boston, Massachusetts, 02125.
Grant RuddDepartment of Engineering, University of Massachusetts, Boston, Massachusetts, 02125.
Amjad P KhanWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.
Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.
Yiran LiuDepartment of Physics, University of Massachusetts, Boston, Massachusetts, 02125.
Filip CuckovDepartment of Engineering, University of Massachusetts, Boston, Massachusetts, 02125.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.
Jonathan P CelliDepartment of Physics, University of Massachusetts, Boston, Massachusetts, 02125.

Funding

Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of OralUH3CA189901 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CELLI, JONATHAN P, HASAN, TAYYABA · 2016 to 2019
$2.7M
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of OralUH2CA189901 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CELLI, JONATHAN P, HASAN, TAYYABA · 2014 to 2015
$995k
VisualSonics Photoacoustic and Ultrasound Imaging SystemS10OD012326 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2012 to 2012
$912k
NCI NIH HHS UH2 CA189901NCI NIH HHS UH3 CA189901NIH HHS S10 OD012326
6 · The paper itself

Abstract

backgroundPhotodynamic therapy (PDT) using δ-aminolevulinic acid (ALA) photosensitization has shown promise in clinical studies for the treatment of early-stage oral malignancies with fewer potential side effects than traditional therapies. Light delivery to oral lesions can also carried out with limited medical infrastructure suggesting the potential for implementation of PDT in global health settings.

objectivesWe sought to develop a cost-effective, battery-powered, fiber-coupled PDT system suitable for intraoral light delivery enabled by smartphone interface and embedded electronics for ease of operation.

methodsDevice performance was assessed in measurements of optical power output, spectral stability, and preclinical assessment of PDT response in ALA-photosensitized squamous carcinoma cell cultures and murine subcutaneous tumor xenografts.

resultsThe system achieves target optoelectronic performance with a stable battery-powered output of approximately 180 mW from the fiber tip within the desired spectral window for PpIX activation. The device has a compact configuration, user friendly operation and flexible light delivery for the oral cavity. In cell culture, we show that the overall dose-response is consistent with established light sources and complete cell death of ALA photosensitized cells can be achieved in the irradiated zone. In vivo PDT response (reduction in tumor volume) is comparable with a commercial 635 nm laser.

conclusionsWe developed a low-cost, LED-based, fiber-coupled PDT light delivery source that has stable output on battery power and suitable form factor for deployment in rural and/or resource-limited settings. Lasers Surg. Med. 9999:1-7, 2018. © 2018 Wiley Periodicals, Inc.

Indexed as

LightAminolevulinic AcidAnimalsAntineoplastic AgentsCarcinoma, Squamous CellCell Line, TumorDeveloping CountriesFemaleHumansMiceMice, NudeMouth NeoplasmsOptical FibersPhotochemotherapyPhotosensitizing AgentsSmartphoneAminolevulinic AcidAntineoplastic AgentsPhotosensitizing Agentsaminolevulinic acid (ALA)global healthlight emitting diode (LED)Oral Cancerphotodynamic therapy (PDT)protoporphhyrin IX (PpIX)

Identifiers

PMID30168618
PMCPMC6934354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.